![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 26, 20027-20032, June 30, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, June 14, 1999, and in revised form, March 16, 2000
Goodpasture syndrome is an autoimmune
disease of the kidneys and lungs mediated by antibodies and T-cells
directed to cryptic epitopes hidden within basement membrane hexamers
rich in Type IV collagen is expressed as six distinct Goodpasture syndrome is an autoimmune disease characterized by the
presence of rapidly progressive glomerulonephritis, pulmonary hemorrhage, and antibodies to the GBM (4, 7). These anti-GBM antibodies
bind primarily to the NC1 domains of the Goodpasture epitopes in vertebrate tissue are normally invisible to the
immune system. Even after biochemical isolation, NC1 hexamers are
usually nonreactive with Goodpasture autoantibodies unless their
complex structure undergoes a physiochemical change in conformation (7,
13, 17). Exposure of these sites is prerequisite for the disease, and
hydrocarbons or viral infection have been suggested as possible
environmental drivers (13, 18). Firm experimental evidence for a
physiologic mediator or mechanism of exposure is not available. Because
the by-products of aerobic metabolism can alter the structural
integrity of macromolecules over time (19), we have evaluated the
capacity of reactive oxygen species (ROS) to expose Goodpasture epitopes.
Basement Membrane Preparations--
Normal portions of human
kidneys were obtained from nephrectomized kidneys with cancer and/or
normal kidneys not used for transplantation. NC1 hexamers were prepared
from renal cortex by detergent extractions (47-49).
Reactions to Generate ROS--
ROS were generated by an in
vitro Fenton reaction (Fe2+ + H2O2
For experiments using inhibitors and scavengers of ROS, we added excess
of inhibitors and scavengers to the reaction mixture before the
addition of FeCl2 or H2O2 (30).
Briefly, desferrioxamine and dimethylthiourea were added at four
different concentrations from 0.1 mM to 1 mM.
Catalase was added at four different concentrations from 0.1 mM to 1 mM. 4-5-µm human kidney sections
were also used in selected experiments as substrate, instead of
purified hexamers, to expose the Goodpasture epitope by the Fenton
reaction. The reaction time for the human kidney sections was 90 min
instead of 16 min, and the final concentration of
FeCl2·4H2O used was 0.5 mM for
these experiments.
Analysis of ROS-treated NC1 Hexamer--
For ELISA of treated
and control NC1 hexamers, sample material recovered from the Fenton
reaction was precipitated with 10 volumes of 95% ethanol,
resolubilized in 10 ml of 50 mM sodium carbonate, pH 9.7, and used to coat ELISA plates in triplicate in 200-µl aliquots.
Direct ELISA was performed as described previously (9, 10, 12, 13, 50).
Goodpasture antibodies (LL), Alport In Vivo Generation of ROS--
In vivo generation of
ROS was performed via modification of the method of Yoshioka et
al. (51). Male Harlan Sprague-Dawley rats weighing between 300 and
400 g were anesthetized with 100 mg/kg Inactin and the abdomen
exposed with a midline ventral incision. The right renal artery was
cannulated via the superior mesenteric artery with a glass cannula and
the right kidney flushed with 1 ml of 0.9% sodium chloride. Perfusion
was then performed for 30 min with 70 mM
H2O2 in a buffer containing 50 mM
NaPO4, pH 7.0, at 22 ml/minute with coinfusion of 150 ml of
0.9% saline/min to maintain arterial patency. Saline-infused rats did
not reveal ultrastructural damage, proving that perfusion pressure was
not a factor in tissue damage. Control perfusions were performed in the
absence of H2O2 or in the presence of
H2O2 with 100 mM catalase, 100 mM dimethylthiourea, and 100 mM
desferrioxamine. After a 30-min H2O2 perfusion,
the kidney was flushed with 0.5 ml of saline and either 10 mg of
Goodpasture IgG or 1 mg of sheep anti-rat GBM. IgG was infused into the
kidney and allowed to incubate for 1 h in a volume of 0.5 ml of
saline. The rat was then sacrificed, and the kidneys surgically
removed, transsected, and frozen immediately in liquid nitrogen for
immunofluorescence staining as described above.
Anti- Statistics--
Results are presented as the mean ± S.E.
The analysis of variance and significance by Student's t
test are reported where appropriate.
Exposure of Goodpasture Epitope by ROS--
In this study we
examined the ability of ROS to expose type IV collagen NC1 hexamers
containing Goodpasture epitopes on
In a second experiment, we kinetically measured the binding of two
rabbit polyclonal antibodies raised to peptides containing the putative
Goodpasture epitopes ( Structural Changes Are Induced in the Type IV Collagen NC1 Hexamer
by ROS--
The changes in the structure, stability, antigenicity, and
function of proteins exposed to ROS have been studied in many
laboratories from a quantitative perspective (21). To evaluate further
the effect of ROS on the structural integrity of NC1 hexamers, aliquots of treated hexamer were analyzed at different time points by gel electrophoresis. These results demonstrate that hexamers remain intact
for the first 6 min of the reaction (Fig.
2) but soon undergo a rapid fragmentation
and ultimately aggregation which are easily detected by 14 min.
Exposure of the Goodpasture epitopes observed between 4 and 6 min
before fragmentation/aggregation maybe due to early conformational
modifications in the hexamer (secondary or tertiary) prior to
shredding.
Inhibition of ROS-mediated Exposure of Goodpasture Epitope--
To
evaluate the specificity of the ROS exposing the Goodpasture epitopes,
we next performed Fenton reactions in the presence of metal chelators,
scavengers, and inhibitors. When dimethylthiourea, a scavenger of
hydroxyl radical, was used in excess, about a 30% reduction was
observed in binding by Goodpasture antibodies to NC1 hexamers (Fig.
3A). These results suggest
that hydroxyl radicals may be one of the species contributing to the
exposure of Goodpasture epitopes. When catalase, an inhibitor of
H2O2, was used in excess, the exposure of
Goodpasture epitope was also diminished by more than 50% (Fig.
3B). Finally, use of the iron chelator, desferrioxamine, in
the Fenton reaction with NC1 hexamers led to a 70% reduction in the
binding of Goodpasture antibodies (Fig. 3A). These results suggest that H2O2 may mediate the exposure of
epitope by itself or by the addition of
FeCl2·4H2O-dependent species to
the microenvironment of the reaction. Although these two species of
radicals are substantially culpable, our experiments at this point do
not preclude the capacity of superoxide anions to also play a role.
In Vivo Exposure of Goodpasture Epitope by ROS--
Several
previous reports have suggested that the binding of human Goodpasture
antibodies to GBM in tissue sections from normal kidneys first requires
denaturation (18, 19, 22-26). To understand this requirement further,
we designed experiments to generate ROS in the presence of human kidney
sections. ROS generated on these sections were evaluated for their
capacity to expose the Goodpasture epitope in tissue. The reaction was
carried out on the kidney section for 15 min, after which the sections
were rinsed exhaustively using 10 mM PBS containing 1%
bovine serum albumin. The sections were then probed with Goodpasture
antibodies, Alport alloantibodies, or normal human serum by indirect
immunofluorescence. Goodpasture antibodies demonstrated a significant
binding to GBM in treated sections (Fig.
4B), whereas only a faint
signal was observed on the untreated sections (Fig. 4A).
Alport alloantibodies bound well to untreated sections (Fig.
4C), but this signal was reduced in sections pretreated with
ROS (Fig. 4D). As an additional control, when acetone-fixed
sections were used (6), the Goodpasture autoantibodies bound strongly
to GBM (data not shown). Normal human serum did not bind to the GBM of
treated kidney sections (data not shown).
In vivo perfusion of Goodpasture autoantibody in the control
rat kidney failed to yield demonstrable binding to the GBM (Fig. 5A), whereas sheep anti-rat
GBM polyclonal antibody provided a linear staining under these
conditions (Fig. 5B). In vivo generation of ROS
via H2O2 perfusion prior to antibody incubation
resulted in a marked increase in binding of the Goodpasture
autoantibody (Fig. 5C), with no significant alteration in
control antibody binding (Fig. 5D). Coinfusion of catalase,
dimethylthiourea, and desferrioxamine with H2O2
substantially diminished binding of the Goodpasture autoantibody (Fig.
5E). Thus, generation of ROS in vivo resulted in
exposure of Goodpasture epitope in the GBM and subsequent binding of
the Goodpasture autoantibody.
Additionally, normal mice treated with 150 mM
H2O2 every 12 h (intravenously) for 14 days were analyzed for endogenous circulating anti-GBM collagen
antibodies. The GBM collagen is predominantly composed of the Several studies have reported that superoxide,
H2O2, and hydrogen radicals can induce
proteinuria in rats and mice (27). Superoxide dismutase, an inhibitor
of superoxide, is also effective in blocking albumin permeability that
has been induced by superoxide in isolated glomeruli (28).
Additionally, desferrioxamine, an iron chelator, and dimethylthiourea,
a hydroxyl radical scavenger, have been effective in treating
proteinuria in anti-GBM disease in rats (29). Dimethylthiourea was also
reported to improve proteinuria in passive Heymann's nephritis (30,
31). These results strongly favor a role for ROS in renal injury. We
now have evaluated the capacity of ROS to denature the NC1 hexamer and
expose immunologically privileged Goodpasture epitopes through alterations in secondary or tertiary structure, fragmentation, or
protein aggregation.
Using bovine serum albumin as a model protein, several studies have
observed that exposure to ROS leads to gross structural alterations in
the protein (30-36). Moreover, in a recent study of aggregation,
fragmentation, and amino acid modifications of 17 proteins by ROS, it
was found that all proteins underwent alterations in molecular weight
(aggregation and fragmentation) or net electric charge associated with
a loss of tryptophan or production of bityrosine (35). It has been
suggested that superoxide alone produced no measurable effect on the
above mentioned parameters and that hydrogen radicals were probably the
initiating species in all cases.
ROS in the current report produced structural changes to the NC1
hexamers and increased the visibility of Goodpasture epitopes within 4 min of the reaction and before fragmentation or aggregation began, as
revealed by gel electrophoresis of the NC1 hexamer at 6 min of the
reaction. Fragmentation of the NC1 hexamer begins by 6 min of reaction,
and eventually aggregation of the protein occurs, some of which remains
in the stacking gel. The aggregates could potentially be from the
smaller fragments of the NC1 hexamer or NC1 hexamer itself.
It is not clear which of these ROS-affected components of the NC1
hexamer best expose Goodpasture epitopes. Studies using the inhibitors
of H2O2 and hydroxyl radicals, and an iron
chelator reveal that none of these modifiers individually could
decrease the appearance of products from the Fenton reaction exposing
relevant epitopes. These experiments suggest that more than one
reactive species is likely mediating the exposure. A similar broad
range of ROS is thought to contribute to the inflammatory events
producing anti-GBM disease in rodents, and more than one reactive
species can induce proteinuria in these experiment systems (18, 19, 21,
27).
Several studies have also reported the capacity of epithelial cells and
mesangial cells isolated from glomeruli to produce ROS in response to
plasma membrane perturbations (30). In response to PMA, for example,
rat glomeruli showed a marked increase in ROS production which reached
a peak at about 20 min and declined gradually thereafter (37). Results
with enzymatic and chemical scavengers of oxygen metabolites suggest a
role for superoxide anion, H2O2, and hydrogen
radicals. These findings further support the notion that ROS can be
generated by resident cells on or near GBM and hence can potentially
alter the structural integrity of NC1 hexamers in the basement membrane.
ROS can be produced in response to various normal stimuli such as
mediators of inflammation, environmental toxins, de novo respiratory bursts associated with the mitochondria electron transport chain, endoplasmic reticulum and nuclear membrane electron transport systems, the prostaglandin synthase and lipooxygenase systems, and
xenobiotics (38, 39). Additionally, ROS may influence GBM degradation
by proteolytic enzymes (40). Pretreatment of rat GBM with
H2O2 increases its susceptibility to
degradation by proteases (41). In this regard, ROS by themselves have
been shown to increase the expression of matrix metalloproteinase-9 by
the glomerular epithelial cells. Therefore, the presence of ROS in the
microenvironment around the GBM can likely activate several pathways of
protein modification.
Finally, infusion of H2O2 into the rat renal
artery produced local generation of ROS and induce a marked glomerular
protein leak within minutes, suggesting an alteration in the integrity of the GBM. In these studies, there was no change in mean arterial pressure, single kidney glomerular filtration rate, or renal plasma flow, suggesting that at least acutely, local generation of ROS by this
technique does not result in marked destruction of the normal renal
architecture. To determine if H2O2-induced
alteration of GBM integrity resulted in unmasking of the Goodpasture
epitopes in vivo (as it was found in the in vitro
studies using NC1 hexamers and human kidney sections), we infused
Goodpasture autoantibodies into the renal artery of either control rats
or rats pretreated with H2O2. As predicted,
infusion of the Goodpasture autoantibodies into control rat kidneys
failed to result in antibody binding, even though a control antibody
directed against multiple epitopes in the GBM demonstrated linear
binding to the GBM under these conditions. However, infusion of
H2O2 into the kidney to induce in
vivo generation of ROS resulted in exposure of the Goodpasture epitope and subsequent Goodpasture antibody binding. Additionally, we
show that infusion of H2O2 in mice for several
days can generate de novo anti- Although some degree of antigen exposure is essential for
immunogenicity, the low frequency of clinical anti-GBM disease (18, 19,
24, 25, 41) suggests that normal exposure of epitopes by self-limited
generation of ROS is not sufficient by itself to launch a fatal
autoimmune response. Additional permissive factors for disease almost
certainly are immunogenetic (18, 19, 24, 25, 41), including
susceptibility in humans that maps to the class II HLA-D region (42,
43) and further restricted by the selection of immunoglobulin GM
allotypes (43, 44). Recent studies in mice also indicate that
immunologic susceptibility to Goodpasture syndrome is closely linked to
the emergence of a Th1-dependent, cell-mediated repertoire
(43-45).
Because most humans with this disease are in mid-life when they become
ill (8), there must be other latent environmental or genetic drivers
that finely modulate susceptibility. The findings from our work raise
the possibility of an age-dependent deterioration of native
ROS inhibitors as an initiator of autoimmune injury. This hypothesis
resonates easily with a more traditional notion of sporadic events that
produce structural protein modification in We thank Prof. Subba Rao Kalluri and Prof.
Sudhir V. Shah for suggestions and helpful discussions during the
course of this study. We appreciate greatly the excellent technical
assistance of Kate Spokes, Beth Shurtleff, and Michelle C. Werner, and
we also thank Meier am Pfarrplatz (Grinzing) for inspiration and support.
*
This work was supported in part by Grants DK-51711 and
DK-55001 from the National Institutes of Health (to R. K.), the 1998 American Society of Nephrology Carl Gottschalk Award, the 1998 National
Kidney Foundation Murry Award (to R. K.), and Grants DK-46282,
DK-07006, DK-30280, and DK-45191 from the National Institutes of Health
(to E. G. N.), Grant DK-48871 from the National Institutes of Health
(to L. G. C.), and the Austrian Fonds Zur Forderung der
Wissenschaftlichen Forschung, Sonderforschungsbereich 5, Project 007 (to D. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Division of
Nephrology, Dept. of Medicine, DANA 563a, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215. Tel.: 617-667-0445; Fax:
617-975-5663; E-mail: rkalluri@Caregroup.Harvard.edu.
Published, JBC Papers in Press, March 23, 2000, DOI 10.1074/jbc.M904549199
The abbreviations used are:
NC1, non-collagenous
globular;
GBM, glomerular basal membrane;
ROS, reactive oxygen species;
H2O2, hydrogen peroxide;
PBS, phosphate-buffered saline;
ELISA, enzyme-linked immunosorbent
assay.
Reactive Oxygen Species Expose Cryptic Epitopes Associated
with Autoimmune Goodpasture Syndrome*
§¶,
,
, and
Division of Nephrology, Department of
Medicine, Beth Israel Deaconess Medical Center and Harvard Medical
School, Boston, Massachusetts 02215, the
Institute of Clinical
Pathology, University of Vienna, Vienna A1090 Wien, Austria, the
§ Penn Center for Molecular Studies of Kidney Diseases,
Department of Medicine, the Cell and Molecular Biology Graduate Group,
University of Pennsylvania, Philadelphia, Pennsylvania 19104, and the
** Nephrology and Hypertension Division, Vanderbilt University,
Nashville, Tennessee 37240
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3 non-collagenous globular (NC1) domains of type IV
collagen. These epitopes are normally invisible to the immune system,
but this privilege can be obviated by chemical modification. Endogenous
drivers of immune activation consequent to the loss of privilege have
long been suspected. We have examined the ability of reactive oxygen
species (ROS) to expose Goodpasture epitopes buried within NC1 hexamers obtained from renal glomeruli abundant in
3(IV) NC1 domains. For
some hexameric epitopes, like the Goodpasture epitopes, exposure to ROS
specifically enhanced recognition by Goodpasture antibodies in a
sequential and time-dependent fashion; control binding of epitopes to
3(IV) alloantibodies from renal transplant recipients with Alport syndrome was decreased, whereas epitope binding to heterologous antibodies recognizing all
3 NC1 epitopes remained the
same. Inhibitors of hydrogen peroxide and hydroxyl radical scavengers
were capable of attenuating the effects of ROS in cells and kidney by
30-50%, respectively, thereby keeping the Goodpasture epitopes
largely concealed when compared with a 70% maximum inhibition by iron
chelators. Hydrogen peroxide administration to rodents was sufficient
to expose Goodpasture epitope in vivo and initiate autoantibody production. Our findings collectively suggest that ROS can
alter the hexameric structure of type IV collagen to expose or destroy
selectively immunologic epitopes embedded in basement membrane. The
reasons for autoimmunity in Goodpasture syndrome may lie in an
age-dependent deterioration in inhibitor function modulating oxidative damage to structural molecules. ROS therefore may
play an important role in shaping post-translational epitope diversity
or neoantigen formation in organ tissues.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
chains that are
assembled selectively into triple helices for incorporation into
basement membranes. These
chains have three domains: the non-collagenous NH2-terminal 7 S domain, a middle triple
helical region containing a characteristic
Gly-X-Y motif, and a COOH-terminal non-collagenous globular (or
NC1)1 domain (1). The type IV
collagen protomer is a triple helical molecule composed of three
polypeptide
chains. With six
chains of type IV collagen, 56 different combinations of type IV collagen protomers are theoretically
possible. In basement membrane these protomers interact with their
neighbors; four 7 S domains interact to form a tetrad, and each NC1
domain abuts with an adjacent NC1 to form a globular hexamer (1-3).
1 and
2 chains are present ubiquitously in nearly all basement
membranes (1, 4, 5), whereas
3,
4,
5, and
6 chains have a
much more restricted distribution (1, 4, 5). The
1 and
2 chains
are fetal isoforms in the renal glomerulus, but later in capillary
development the glomerular basement membrane (GBM) undergoes an isoform
switch and
3,
4, and
5 chains replace and predominate in the
adult nephron (6).
3 chain of type IV collagen
(4, 8-16) and are found in all patients with the disease (4, 7-16).
Circulating and tissue-bound (kidney and lung) antibodies recognize
epitopes on the
3(IV) chain located in the NC1 domain (12, 13).
Whether these epitopes form a single conformational binding site in
their native state is not yet clear.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Fe3+ + OH· + OH
) in the presence of human type IV collagen NC1
hexamers. FeCl2, H2O2, catalase,
dimethylthiourea, and desferrioxamine were purchased from Sigma. The
reactions were set up in polyethylene tubes using H2O2, FeCl2, 50 mM PBS,
and the renal NC1 hexamers. Briefly, 10 µg of human NC1 hexamer was
solubilized in 150 µl of 50 mM PBS for each reaction. To
this solution, 100 mM FeCl2·4H2O
was added to a final concentration of 0.3 mM. 1 min later,
5 M H2O2 was added to a final
concentration of 1 mM. The reaction was carried out at
4 °C for 16 min with gentle stirring. A 20-µl aliquot was taken
from the reaction at 2-min intervals. Each aliquot of sample was then
analyzed by ELISA, gel electrophoresis, and Western blotting described below.
3(IV) alloantibodies (a
particular patient's antibody with reactivity to
3NC1 domain (20)),
3-c.36 peptide antibody,
3-n.26 peptide antibody, and
3 NC1
antibody (6, 13, 48) were used as primary antibodies in various
experiments. All antibodies were used at a dilution of 1:50, except the
Alport alloantibodies were used at 1:500. For gel electrophoresis, each
aliquot sample (after ethanol precipitation) was mixed with an equal
volume of gel loading buffer and resolved by nondenaturing gel
electrophoresis (11). In some experiments, these gel samples were
transferred for Western blotting (11). Goodpasture antibodies (1:50
dilution) and Alport alloantibodies (1:500 dilution) were used as
primary antibodies for indirect immunofluorescent staining of human
kidney pretreated with the Fenton reaction. Immunofluorescent staining
was performed as described previously and washed three times with 10 mM PBS containing 1% bovine serum albumin (11). The
staining with primary antibody was developed using fluorescent
isothiocyanate-rabbit anti-human IgG (6).
3(IV) NC1 Antibody Production by Hydrogen
Peroxide--
Three normal mice (BALB/c) weighing 20 g were
intravenously (tail vein) injected with 150 mM
H2O2 every 12 h for 14 days. The mice were
sacrificed after 14 days, and the blood was collected. The serum
samples from these mice were evaluated for circulating antibodies
toward the Goodpasture antigen (
3(IV) NC1 domain) using direct
ELISA, as described above. The recombinant
3,
4, and
5 NC1
were generated as described previously (13, 14). These are denatured
proteins, and the recombinant
3 NC1 binds to Goodpasture
autoantibodies (13, 14). The NC1 hexamer (as described above) is a
native structure, and previous studies have shown that Goodpasture
autoantibodies bind weakly to this structure and upon denaturation by
urea, acid, or ROS (as presented in Fig. 1 in this paper), the binding
to Goodpasture autoantibodies increases by severalfold. Placenta type
IV collagen was purchased from Sigma.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3 chains. Our results demonstrate
that Goodpasture epitopes are not normally visible to Goodpasture
autoantibodies in native isolated NC1 hexamers from GBM, but the
antibodies will bind to hexamer preparations pretreated with ROS in a
time-dependent fashion (Fig. 1A). Briefly, 10 µg of human
NC1 hexamer was solubilized in 150 µl of 50 mM PBS for
each reaction. To this solution, 100 mM
FeCl2·4H2O was added to a final concentration
of 0.3 mM. 1 min later, 5M H2O2 was added to a final concentration of 1 mM. The reaction was carried out at 4 °C for 16 min with
gentle stirring. A 20-µl aliquot was taken from the reaction at 2-min
intervals. Each aliquot of sample was then analyzed by ELISA, gel
electrophoresis, and Western blotting. Goodpasture antibodies
recognized ROS-modified NCI hexamers beginning 4 min after initiation
of the Fenton reaction with maximum binding achieved by 14 min. Normal
human serum did not bind to pretreated hexamers. Alport transplant
alloantibodies, which also recognize multiple epitopes on the
3(IV)
NC1 domain in some patients (6, 20), initially demonstrated a strong recognition at 2 min but gradually decreased their binding over the
lengthening time of treatment with ROS. By 14 min, binding had
plateaued by 75%, an effect similar to what was observed previously using 6 M guanidine HCl to denature hexamers (13). These
results collectively suggest that ROS are capable of altering the
epitope structure of NC1 hexamers differentially and that Goodpasture antibodies and the Alport transplant antibodies, whereas recognizing the same NC1 domain, generally bind to different sets of epitopes.

View larger version (18K):
[in a new window]
Fig. 1.
Exposure of Goodpasture epitope by ROS.
Panel A, open rectangles denote human Goodpasture
autoantibodies (1:50 dilution), open circles denote normal
human serum (1:50 dilution), and dark circles denote Alport
alloantibodies (1:500 dilution). Panel B, dark
circles denote anti-NC1 antibodies (1:50 dilution), dark
rectangles denote rabbit anti-
3c.36 peptide antibody (1:50
dilution), and open rectangles denote rabbit anti-
3n.26
peptide antibody (1:50 dilution). The methods are as described in
detail under "Experimental Procedures."
3-n.26 and
3-c.36) to hexamers pretreated
with ROS (Fig. 1B). In the absence of ROS pretreatment, neither
3-n.26 nor
3-c.36 bound substantially to the NC1 hexamer, whereas a polyclonal positive control antibody raised against all
visible epitopes expressed by intact NC1 hexamers (160 kDa;
3NC1)
did bind NC1 hexamers and did not lose binding capacity over the 16-min
exposure of NC1 hexamer to ROS, suggesting that most epitopic
structures on these NC1 hexamers were not destroyed by ROS. After a
16-min exposure to ROS, both anti-
3-n.26 peptide antibody directed
to the first 26 amino acid residues of the NH2-terminal and
anti-
3-c.36 peptide antibody directed to the last 36 residues containing the COOH-terminal epitope in the
3(IV)NC1 bound equally well to the NC1 hexamer and the control antibody, demonstrating that
all epitopes were now exposed for binding. However, during the time
course of the experiment, anti-
3-n.26 bound earlier and more
strongly to the NC1 hexamers than the
3-c.36 antibody. Because the
binding titers for all three antibodies were predetermined to be
similar and in the linear range of binding (data not shown and (13)),
these experiments demonstrate that not all epitopic regions of the
3(IV) NCI domain are altered by exposure to ROS and that the two
principal Goodpasture epitopes in the
3(IV) NCI domains may open in
a preferred order.

View larger version (94K):
[in a new window]
Fig. 2.
Gel electrophoresis analysis of ROS-treated
type IV collagen NC1 hexamer. ROS-treated and untreated NC1
hexamer was analyzed by nondenaturing gel electrophoresis. 1-mg
aliquots of samples were used for this analysis. Lane 1,
untreated NC1 hexamer, shown by an arrow. The molecular mass
of this band is about 160 kDa, as described previously (11). Lane
2, ROS-treated NC1 hexamer (2 min). This sample resembles
untreated hexamer. There is no significant fragmentation or
aggregation. Lane 3, ROS-treated NC1 hexamer (6 min). The
hexamer band is less intense compared with the control, and there is
some fragmentation. Lane 4, ROS-treated NC1 hexamer (10 min). The hexamer band is vastly diminished, and a smear of lower
molecular mass fragments is prominent. Lane 5, ROS-treated
NC1 hexamer (14 min). The lower molecular mass fragments are visible
with two prominent bands (arrowheads). High molecular mass
aggregation products are also visible in this lane. The gel was stained
with Coomassie Blue for 5 h and destained with 10% acetic acid
and 5% methanol at room temperature.

View larger version (33K):
[in a new window]
Fig. 3.
Inhibition experiments. ELISA was
performed after 14 min of ROS treatment of NC1 hexamer with and without
inhibitors. Panel A, desferrioxamine and dimethylthiourea
treatment. Panel B, catalase treatment. The Goodpasture
antibodies were used at a dilution of 1:50, and the NC1 hexamer
(treated or untreated) was coated at a concentration of 100 ng/well.

View larger version (162K):
[in a new window]
Fig. 4.
Immunofluorescence experiments. Human
kidney sections were probed with Goodpasture autoantibodies and Alport
alloantibodies before or after treatment with ROS. Panels B
and D are 4 mM human kidney sections treated
with ROS, and panels A and C are untreated
sections. Panel A and B, Goodpasture
autoantibodies; panels C and D, Alport
alloantibodies. Goodpasture autoantibodies were used at a 1:50
dilution. Alport alloantibodies were used at a 1:500 dilution. All
sections were probed with fluorescent isothiocyanate-conjugated goat
anti-human antibodies (1:50) subsequent to primary antibody incubation.
Magnification, × 400.

View larger version (93K):
[in a new window]
Fig. 5.
Exposure of Goodpasture epitope in
vivo. Panel A, Goodpasture autoantibodies on
control rat kidney. Panel B, sheep anti-rat GBM antibodies
on control rat kidney section. Panel C, Goodpasture
autoantibodies on kidney section from rat pretreated with
H2O2. Panel D, sheep anti-rat GBM
antibodies on on kidney a section from rat pretreated with
H2O2. Panel E, Goodpasture
antibodies on kidney from rat coinfused with
H2O2 in the presence of catalase,
dimethylthiourea, and desferrioxamine. Magnification, × 400
3,
4, and
5 isoforms in mammals (6). Direct ELISA experiments show
that H2O2-treated mice develop significant anti-
3(IV)NC1 titers (Fig. 6) in
addition to weaker responses
4 and
5 NC1 domain. Some Goodpasture
patients also show weaker antibodies to other chains, potentially of
insignificant pathological consequence (10). The ROS-initiated
anti-
3 antibody was directed to a cryptic epitope within the NC1
hexamer, similar to human Goodpasture autoantibodies (Fig. 6). These
results strongly suggest that ROS are capable of exposing Goodpasture
epitope, thus initiating a humoral response to this pathogenic antigen.

View larger version (24K):
[in a new window]
Fig. 6.
Production of
3(IV)NV1 antibodies in vivo.
Direct ELISA was performed as described under "Experimental
Procedures." Normal mouse serum and serum from mice treated with
H2O2 were used at a dilution of 1:25 in all
experiments. Each well (triplicates) was coated with 200 ng of
denatured recombinant type IV collagen
NC1 domains, native NC1
hexamer, or native type IV collagen. Anti-mouse IgG antibody conjugated
to alkaline phosphatase was used for detection of mouse antibody
binding to the antigens. All absorbance 405 nm values are an average of
triplicate readings. p < 0.05 by one-tailed Student's
t test.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3(IV) collagen antibodies,
further supporting the notion that ROS can be responsible for in
vivo generation of Goodpasture autoantibodies.
3(IV) NC1 domains
permitting immunologic recognition in a disease-susceptible host (46).
It remains to be determined whether ROS scavengers could have an
epitope-protective therapeutic effect in Goodpasture patients.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Hudson, B. G.,
Reeders, S. T.,
and Tryggvason, K.
(1993)
J. Biol. Chem.
268,
26033-26036
2.
Timpl, R.,
Wiedemann, H.,
Van Veldon, V.,
Furthmayr, H.,
and Kuhn, K.
(1981)
Eur. J. Biochem.
120,
203-211
3.
Timpl, R.,
Oberbaumer, I.,
von der Mark, H.,
Bode, W.,
Wick, G.,
Weber, S.,
and Engel, J.
(1985)
Ann. N. Y. Acad. Sci.
460,
58-72
4.
Hudson, B.,
Kalluri, R.,
Gunwar, S.,
Noelken, M.,
Mariyama, M.,
and Reeders, S.
(1993)
Kidney Int.
43,
135-139
5.
Tryggvason, K.,
Soininen, R.,
Hostikka, S. L.,
Ganguly, A.,
Huotari, M.,
and Prockop, D. J.
(1990)
Ann. N. Y. Acad. Sci.
580,
97-111
6.
Kalluri, R.,
Shield, F. A.,
Todd, P.,
Hudson, B. G.,
and Neilson, E. G.
(1997)
J. Clin. Invest.
99,
2470-2478
7.
Hudson, B. G.,
Wieslander, J.,
Wisdom, B. J. J.,
and Noelken, M. E.
(1989)
Lab. Invest.
61,
256-269
8.
Ryan, J. J.,
Mason, P. J.,
Pusey, C. D.,
and Turner, N.
(1998)
Clin. Exp. Immunol.
113,
17-27
9.
Kalluri, R.,
Gunwar, S.,
Reeders, S. T.,
Morrision, K. C.,
Mariyama, M.,
Ebner, K. E.,
Noelken, M. E.,
and Hudson, B. G.
(1991)
J. Biol. Chem.
266,
24018-24024
10.
Kalluri, R.,
Wilson, C. B.,
Weber, M.,
Gunwar, S.,
Chonko, A. M.,
Neilson, E. G.,
and Hudson, B. G.
(1995)
J. Am. Soc. Nephrol.
6,
1178-1185
11.
Kalluri, R., V.,
Gattone, V. H., Jr.,
Noelken, M. E.,
and Hudson, B. G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
6201-6205
12.
Hellmark, T.,
Segelmark, M.,
Unger, C.,
Burkhardt, H.,
Saus, J.,
and Wieslander, J.
(1999)
Kidney Int.
55,
936-944
13.
Kalluri, R.,
Sun, M. J.,
Hudson, B. G.,
and Neilson, E. G.
(1996)
J. Biol. Chem.
271,
9062-9068
14.
Neilson, E. G.,
Kalluri, R.,
Sun, M. J.,
Gunwar, S.,
Danoff, T.,
Mariyama, M.,
Myers, J. C.,
Reeders, S. T.,
and Hudson, B. G.
(1993)
J. Biol. Chem.
268,
8402-8405
15.
Turner, N.,
Mason, P. J.,
Brown, R.,
Fox, M.,
Povey, S.,
Rees, A.,
and Pusey, C. D.
(1992)
J. Clin. Invest.
89,
592-601
16.
Hellmark, T.,
Johansson, C.,
and Wieslander, J.
(1994)
Kidney Int.
46,
823-829
17.
Wieslander, J.,
Langeveld, J.,
Butkowski, R.,
Jodlowski, M.,
Noelken, M.,
and Hudson, B. G.
(1985)
J. Biol. Chem.
260,
8564-8570
18.
Wilson, C. B.
(1996)
in
The Kidney
(Brenner, B., ed)
, pp. 1253-1391, W. B. Saunders, Philadelphia
19.
Sohal, R. S.,
and Weindrch, R.
(1996)
Science
273,
59-63
20.
Hudson, B. G.,
Kalluri, R.,
Gunwar, S.,
Weber, M.,
Ballester, F.,
Hudson, J. K.,
Noelken, N. E.,
Sarras, M.,
Richardson, W. R.,
and Saus, J.
(1992)
Kidney Int
42,
179-187
21.
Marsden, P.,
Hall, A.,
and Brenner, B.
(1996)
in
The Kidney
(Brenner, B., ed)
, pp. 713-781, W. B. Saunders, Philadelphia
22.
Wilson, C. B.,
and Dixon, F. J.
(1973)
Kidney Int.
3,
74-83
23.
Wilson, C. B.,
Holdsworth, S. R.,
and Neale, T. J.
(1981)
Aust. New Zealand J. Med.
11,
94-99
24.
Scheiman, J. I.,
Foidart, J. M.,
and Michael, A. F.
(1980)
Lab. Invest.
43,
373-381
25.
Couser, W. G.
(1988)
Am. J. Kidney Dis.
11,
449-458
26.
Couser, W. G.,
Darby, C.,
Salant, D. J.,
Adler, S.,
Stilmant, M. M.,
and Lowenstein, L. M.
(1985)
Am. J. Physiol.
249,
F241-F250
27.
Diamond, J.
(1992)
Am. J. Kid. Dis.
19,
292-300
28.
Dileepan, K.,
Sharma, R.,
Stechschulte, D.,
and Savin, V.
(1993)
J. Lab. Clin. Med.
121,
797-804
29.
Boyce, N.,
and Holdsworth, S.
(1986)
Kidney Int.
30,
813-817
30.
Shah, S. V.
(1989)
Kidney Int.
35,
1093-1106
31.
Neale T. J., Ullrich R., Ojha, P. P., Poczewski, H.,
Verhoeven, A. J., and Kerjaschki, D. Proc. Natl. Acad. Sci.
U. S. A. 90, 3645-3649
32.
Davies, K. J.,
Lin, S. W.,
and Pacifici, R. E.
(1987)
J. Biol. Chem.
262,
9914-9920
33.
Davies, K. J.,
and Delsignore, M. E.
(1987)
J. Biol. Chem.
262,
9908-9913
34.
Davies, K. J.,
Delsignore, M. E.,
and Lin, S. W.
(1987)
J. Biol. Chem.
262,
9902-9907
35.
Riedle, B.,
and Kerjaschki, D.
(1997)
Am. J. Pathol.
151,
215-231
36.
Pacifici, R. E.,
Lin, S. W.,
and Davies, K. J.
(1988)
Basic Life Sci.
49,
531-535
37.
Shah, S.
(1981)
J. Lab. Clin. Med.
98,
46-57
38.
McCord, J.,
and Fridovich, I.
(1978)
Ann. Intern. Med.
89,
122-127
39.
Freeman, B.,
and Crapo, J.
(1982)
Lab. Invest.
47,
412-426
40.
Shah, S.,
Baricos, W.,
and Basci, A.
(1987)
J. Clin. Invest.
79,
25-31
41.
Fligiel, S.,
Lee, E.,
McCoy, J.,
Johnson, K.,
and Varani, J.
(1984)
Am J. Pathol.
115,
418-425
42.
Rees, A. J.,
Peters, D. K.,
Amos, N.,
Welch, K. I.,
and Batchelor, J. R.
(1984)
Kidney Int.
26,
444-450
43.
Huey, B.,
McCormick, K.,
Crapper, J.,
Ratliff, C.,
Colombe, B. W.,
Garovoy, M. R.,
and Wilson, C. B.
(1993)
Kidney Int.
44,
307-312
44.
Rees, A.,
Demaine, A.,
and Welch, K.
(1984)
Hum. Immunol.
10,
213-220
45.
Kalluri, R.,
Danoff, T. M.,
Okada, H.,
and Neilson, E. G.
(1997)
J. Clin. Invest.
100,
2263-2275
46.
Jennette, C.,
and Falk, R.
(1991)
Immunogenetics of Autoimmune Renal Disease
, pp. 263-281, CRC Press, Boca Raton, FL
47.
Wieslander, J.,
Kataja, M.,
and Hudson, B. G.
(1987)
Clin. Exp. Immunol.
69,
332-340
48.
Gunwar, S.,
Ballester, F.,
Kalluri, R.,
Timoneda, J.,
Chonko, A. M.,
Edwards, S. J.,
Noelken, M. E.,
and Hudson, B. G.
(1991)
J. Biol. Chem.
266,
15318-15324
49.
Butkowski, R. J.,
Wieslander, J.,
Wisdom, B. J.,
Barr, J. F.,
Noelken, M. E.,
and Hudson, B. G.
(1985)
J. Biol. Chem.
260,
3739-3747
50.
Kalluri, R.,
Pettrides, S.,
Wilson, C. B.,
Tomaszewski, J. E.,
Palevsky, H. I.,
Grippi, M. A.,
Madaio, M.,
and Neilson, E. G.
(1996)
Ann. Intern. Med.
124,
651-653
51.
Yoshioka, T.,
Ichikawa, I.,
and Fogo, A.
(1991)
J. Am. Soc. Nephrol.
2,
902-912
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Y. Zhang, S. C. Su, D. B. Hecox, G. F. Brady, K. M. Mackin, A. G. Clark, and M. H. Foster Central Tolerance Regulates B Cells Reactive with Goodpasture Antigen {alpha}3(IV)NC1 Collagen J. Immunol., November 1, 2008; 181(9): 6092 - 6100. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Vanacore, A.-J. L. Ham, J.-P. Cartailler, M. Sundaramoorthy, P. Todd, V. Pedchenko, Y. Sado, D.-B. Borza, and B. G. Hudson A Role for Collagen IV Cross-links in Conferring Immune Privilege to the Goodpasture Autoantigen: STRUCTURAL BASIS FOR THE CRYPTICITY OF B CELL EPITOPES J. Biol. Chem., August 15, 2008; 283(33): 22737 - 22748. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sachse and G. Wolf Angiotensin II Induced Reactive Oxygen Species and the Kidney J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2439 - 2446. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Kang, C. E. Kashtan, A. N. Turner, L. Heidet, B. G. Hudson, and D.-B. Borza The Alloantigenic Sites of {alpha}3{alpha}4{alpha}5(IV) Collagen: PATHOGENIC X-LINKED ALPORT ALLOANTIBODIES TARGET TWO ACCESSIBLE CONFORMATIONAL EPITOPES IN THE {alpha}5NC1 DOMAIN J. Biol. Chem., April 6, 2007; 282(14): 10670 - 10677. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-P. Wang, A. B. Fogo, S. Colon, G. Giannico, S. R. Abul-Ezz, J. H. Miner, and D.-B. Borza Distinct Epitopes for Anti-Glomerular Basement Membrane Alport Alloantibodies and Goodpasture Autoantibodies within the Noncollagenous Domain of {alpha}3(IV) Collagen: A Janus-Faced Antigen J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3563 - 3571. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-B. Borza, O. Bondar, S. Colon, P. Todd, Y. Sado, E. G. Neilson, and B. G. Hudson Goodpasture Autoantibodies Unmask Cryptic Epitopes by Selectively Dissociating Autoantigen Complexes Lacking Structural Reinforcement: NOVEL MECHANISMS FOR IMMUNE PRIVILEGE AND AUTOIMMUNE PATHOGENESIS J. Biol. Chem., July 22, 2005; 280(29): 27147 - 27154. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. G. Hudson The Molecular Basis of Goodpasture and Alport Syndromes: Beacons for the Discovery of the Collagen IV Family J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2514 - 2527. [Full Text] [PDF] |
||||
![]() |
U. Persson, J. M. Hertz, M. Carlsson, T. Hellmark, I. Juncker, J. Wieslander, and M. Segelmark Patients with Goodpasture's disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen {alpha}3 chain Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2030 - 2035. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. G. Hudson, K. Tryggvason, M. Sundaramoorthy, and E. G. Neilson Alport's Syndrome, Goodpasture's Syndrome, and Type IV Collagen N. Engl. J. Med., June 19, 2003; 348(25): 2543 - 2556. [Full Text] [PDF] |
||||
![]() |
H. HOPFER, R. MARON, U. BUTZMANN, U. HELMCHEN, H. L. WEINER, and R. KALLURI The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice FASEB J, May 1, 2003; 17(8): 860 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cha, A.B. Peck, and M.G. Humphreys-Beher PROGRESS IN UNDERSTANDING AUTOIMMUNE EXOCRINOPATHY USING THE NON-OBESE DIABETIC MOUSE: AN UPDATE Crit. Rev. Oral. Biol. Med., January 1, 2002; 13(1): 5 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Gherardi, M. Coquet, P. Cherin, L. Belec, P. Moretto, P. A. Dreyfus, J.-F. Pellissier, P. Chariot, and F.-J. Authier Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle Brain, September 1, 2001; 124(9): 1821 - 1831. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. David, D.-B. Borza, A. Leinonen, J. M. Belmont, and B. G. Hudson Hydrophobic Amino Acid Residues Are Critical for the Immunodominant Epitope of the Goodpasture Autoantigen. A MOLECULAR BASIS FOR THE CRYPTIC NATURE OF THE EPITOPE J. Biol. Chem., February 23, 2001; 276(9): 6370 - 6377. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||